Synthetic Biologics Announces Data And Safety Monitoring Committee (DSMC) Review In Phase 1b/2a Clinical Trial Of SYN-004 (ribaxamase) In Allogeneic Hematopoietic Cell Transplant Recipients
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2